Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Cell Therapy
NeoStem to Present at Six Conferences in June
Posted: June 1, 2012 at 1:12 pm
NEW YORK, May 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company focused on cell based therapies, announced today that Company management will present at six conferences in June.
International Society for Cellular Therapy Annual Meeting
National Investment Banking Association Conference
International Society for Stem Cell Research 10th Annual Meeting
The Biotechnology Industry Organization (BIO) International Conference
Alliance for Regenerative Medicine -- Clinical Outlooks for Regenerative Medicine 2012
Marcum's Inaugural MicroCap Conference
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, LLC, also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and is enrolling patients in a Phase 2 trial for the preservation of heart function after a heart attack. Amorcyte expects to begin a Phase 1 clinical trial in 2012/2013 for AMR-001 for the treatment of patients with congestive heart failure. Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with its partner Becton-Dickinson. NeoStem's pre-clinical assets include its VSEL(TM) Technology platform for regenerative medicine, which NeoStem believes to be an endogenous, pluripotent, non-embryonic stem cell that has the potential to change the paradigm of cell therapy as we know it today.
For more information on NeoStem, please visit http://www.neostem.com.
Read this article:
NeoStem to Present at Six Conferences in June
Posted in Cell Therapy
Comments Off on NeoStem to Present at Six Conferences in June
Dogged by pain — stem cell therapy for dogs.flv – Video
Posted: June 1, 2012 at 12:21 am
30-05-2012 07:05 write to:
Read more:
Dogged by pain -- stem cell therapy for dogs.flv - Video
Posted in Cell Therapy
Comments Off on Dogged by pain — stem cell therapy for dogs.flv – Video
NeoStem to Present at Six Conferences in June
Posted: June 1, 2012 at 12:21 am
NEW YORK, May 31, 2012 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE Amex:NBS) ("NeoStem" or the "Company"), an international biopharmaceutical company focused on cell based therapies, announced today that Company management will present at six conferences in June.
International Society for Cellular Therapy Annual Meeting
National Investment Banking Association Conference
International Society for Stem Cell Research 10th Annual Meeting
The Biotechnology Industry Organization (BIO) International Conference
Alliance for Regenerative Medicine -- Clinical Outlooks for Regenerative Medicine 2012
Marcum's Inaugural MicroCap Conference
About NeoStem, Inc.
NeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, LLC, also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR-001, represents NeoStem's most clinically advanced therapeutic and is enrolling patients in a Phase 2 trial for the preservation of heart function after a heart attack. Amorcyte expects to begin a Phase 1 clinical trial in 2012/2013 for AMR-001 for the treatment of patients with congestive heart failure. Athelos Corporation, also a NeoStem company, is developing a T-cell therapy for a range of autoimmune conditions with its partner Becton-Dickinson. NeoStem's pre-clinical assets include its VSEL(TM) Technology platform for regenerative medicine, which NeoStem believes to be an endogenous, pluripotent, non-embryonic stem cell that has the potential to change the paradigm of cell therapy as we know it today.
For more information on NeoStem, please visit http://www.neostem.com.
Posted in Cell Therapy
Comments Off on NeoStem to Present at Six Conferences in June
Heart-Attack-Patient-Receives-Adult-Stem-Cell-Therapy- – Video
Posted: May 31, 2012 at 10:17 am
30-05-2012 10:25
View original post here:
Heart-Attack-Patient-Receives-Adult-Stem-Cell-Therapy- - Video
Posted in Cell Therapy
Comments Off on Heart-Attack-Patient-Receives-Adult-Stem-Cell-Therapy- – Video
Ottawa’s latest brain gain brings promising new stem-cell therapy
Posted: May 30, 2012 at 7:13 pm
OTTAWA Dr. Bernard Thebaud believes he can use the healing juices from stem cells the much ballyhooed future of modern medicine to rejuvenate the lungs of premature babies.
The renowned neonatologist and scientist has proven his treatment works in rats in Edmonton, and in a baboon in San Antonio, Texas. Next, he will design clinical trials to test his pioneering therapy in babies in Ottawa.
Dr. Thebaud is the latest recruit to the Sprott Centre for Stem Cell Research at the Ottawa Hospital Research Institute.
Lured here from the University of Alberta, Dr. Thebaud hopes that within five years he can take his research from bench to bedside by launching the first clinical trials in newborns.
He believes his therapy, derived from stem cells isolated from discarded umbilical cords, can help people suffering from other lung diseases, such as asthma and fibrosis.
In an interview, the 47-year-old, who is originally from France, said Ottawa was the only city where he could do this research.
To get this work into patients, I need to be around a critical mass of top stem cell biologists, he said.
I dont want to be too clich, but if you are in the computer business you go to the Silicon Valley; if you are in oil in gas you have to be in Alberta; if you are in stem cells, Ontario is the province. And Ottawa is where they read, breathe, sleep and eat stem cells.
To land Thebaud, three Ottawa institutions had to team up.
When he formally starts in the fall, he will be a Senior Scientist at the Ottawa Hospital and CHEO research institutes, a pediatrician at CHEO and Ottawa Hospital, and a professor in the faculty of medicine at the University of Ottawa.
See the rest here:
Ottawa’s latest brain gain brings promising new stem-cell therapy
Posted in Cell Therapy
Comments Off on Ottawa’s latest brain gain brings promising new stem-cell therapy
Stem Cell Therapy: Healing Force of the future – Video
Posted: May 30, 2012 at 3:18 pm
29-05-2012 11:48 In this episode of Breakthrough Medicine, experts from the University of Miami's Interdisciplinary Stem Cell Institute (ISCI) use adult stem cells to repair organs and save lives. In this episode of Breakthrough Medicine, experts from the University of Miami's Interdisciplinary Stem Cell Institute (ISCI) use adult stem cells to repair organs and save lives. A heart attack victim receives his own stem cells in hopes of repairing his damaged heart muscle, and after all other methods have failed, patients with chronic wounds turn to a revolutionary study that heals broken skin. Can you be saved by your own cells? Watch to find out how unlocking the powers of adult stem cells is changing medicine.
Follow this link:
Stem Cell Therapy: Healing Force of the future - Video
Posted in Cell Therapy
Comments Off on Stem Cell Therapy: Healing Force of the future – Video
UCI researcher wins large research grant
Posted: May 30, 2012 at 4:19 am
A UC Irvine stem cell researcher won a $4.8-million grant to fund research toward a treatment for multiple sclerosis.
The California Institute for Regenerative Medicine awarded immunologist Thomas Lane, of the campus' Sue and Bill Gross Stem Cell Research Center, an Early Transitional Award last week to create a new line of neural stem cells to treat multiple sclerosis, according to a UCI press release.
"I am delighted that [the California Institute] has chosen to support our efforts to advance a novel stem cell-based therapy for multiple sclerosis," Peter Donovan, director of the research center, said in the release.
Lane is collaborating with Jeanne Loring, director of the Center for Regenerative Medicine at the Scripps Research Institute in La Jolla, and Claude Bernard, a multiple sclerosis researcher at Monash University in Australia.
The research project "really embodies what [the California Institute] is all about, which is bringing science together to treat horrible diseases like multiple sclerosis," said Lane, who is a professor of molecular biology and biochemistry.
Multiple sclerosis is a central nervous system disease that causes inflammation and a loss of myelin, a fatty tissue that insulates and protects nerve cells.
The three are working on a stem cell treatment that will stop myelin loss while promoting the growth of new myelin to mend damaged nerves.
Loring creates the neural stem cells, said Lane, while he is testing the therapeutic effects the cells have on multiple sclerosis cells in animals.
The stem cells are already having a positive effect and the scientists are trying to understand why. They hope to identify the cells that have the most promise before going to clinical trials.
"I really want to thank the [California Institute] for allowing, and for funding, us," Lane said.
Read this article:
UCI researcher wins large research grant
Posted in Cell Therapy
Comments Off on UCI researcher wins large research grant
CHOC Children’s Research Project Awarded $5.5 Million Grant from the California Institute for Regenerative Medicine
Posted: May 30, 2012 at 4:19 am
ORANGE, Calif.--(BUSINESS WIRE)--
A CHOC Childrens research project, under the direction of Philip H. Schwartz, Ph.D., senior scientist at the CHOC Childrens Research Institute and managing director of the facilitys National Human Neural Stem Cell Resource, has been awarded a $5.5 million grant from the California Institute for Regenerative Medicine (CIRM). The grant will be used to develop a stem cell-based therapy for the treatment of mucopolysaccharidosis (MPS I), a fatal metabolic disease that causes neurodegeneration, as well as defects in other major organ systems.
Based on a number of medical and experimental observations, children with inherited degenerative diseases of the brain are expected to be among the first to benefit from novel approaches based on stem cell therapy (SCT).
Dr. Schwartz explains, While uncommon, pediatric genetic neurodegenerative diseases account for a large burden of mortality and morbidity in young children. Hematopoietic (bone marrow) stem cell transplant (HSCT) can improve some non-neural symptoms of these diseases, but does not treat the deadly neurodegenerative process. Our approach targeting the effects of the disease on organs besides the brain with HSCT and neurodegeneration with a second stem cell therapy specifically designed to treat the brain is a strategy for whole-body treatment of MPS I. Our approach is also designed to avoid the need for immunosuppressive drugs to prevent rejection of the transplanted cells.
This research is designed to lead to experimental therapy, based on stem cells, by addressing two critical issues: early intervention is required and possible in this patient population; and teaching the immune system not to reject the transplanted cells is required. This research also sets the stage for efficient translation of this technology into clinical practice, by adapting transplant techniques that are standard in clinical practice or in clinical trials, and using laboratory cell biology methods that are easily transferrable to clinical cell manufacturing.
Nationally recognized for his work in the stem cell field, Dr. Schwartz research focuses on the use of stem cells to understand the neurobiological causes of autism and other neurodevelopmental disorders.
Named one of the best childrens hospitals by U.S. News & World Report (2011-2012) and a 2011 Leapfrog Top Hospital, CHOC Children's is exclusively committed to the health and well-being of children through clinical expertise, advocacy, outreach and research that brings advanced treatment to pediatric patients.
Posted in Cell Therapy, Stem Cell Therapy
Comments Off on CHOC Children’s Research Project Awarded $5.5 Million Grant from the California Institute for Regenerative Medicine
Biostem U.S., Corporation Appoints Philip A. Lowry, MD as Chairman of Its Scientific and Medical Board of Advisors
Posted: May 29, 2012 at 1:23 pm
CLEARWATER, FL--(Marketwire -05/29/12)- Biostem U.S., Corporation, (HAIR.PK) (HAIR.PK) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, today announced that Philip A. Lowry, MD, has been appointed as the Chairman of its Scientific and Medical Board of Advisors (SAMBA).
According to Biostem CEO, Dwight Brunoehler, "As Chairman, Dr. Lowry will work with a team drawn from a cross-section of medical specialties. His combination of research, academic and community practice experience make him the perfect individual to coordinate and lead the outstanding group of physicians that makes up our SAMBA. As a group, The SAMBA will guide the company to maintain the highest ethical standards in every effort, while seeking and developing new cutting edge technology based on stem cell use. I am privileged to work with Dr. Lowry, once again."
Dr. Lowry stated, "Dwight is an innovative businessman with an eye on cutting-edge stem cell technology. His history in the industry speaks for itself. I like the plan at Biostem and look forward to working with everyone involved."
Dr. Philip A. Lowry received his undergraduate degree from Harvard College before going on to the Yale University School of Medicine. His completed his internal medicine residency at the University of Virginia then pursued fellowship training in hematology and oncology there as well. During fellowship training and subsequently at the University of Massachusetts, he worked in the laboratory of Dr. Peter Quesenberry working on in vitro and in vivo studies of mouse and human stem cell biology.
Dr. Lowry twice served on the faculty at the University of Massachusetts Medical Center from 1992-1996 and from 2004-2009 as an assistant and then associate clinical professor of medicine establishing the bone marrow/stem cell transplantation program there, serving as medical director of the Cryopreservation Lab supporting the transplant program, helping to develop a cord blood banking program, and teaching and coordinating the second year medical school course in hematology and oncology. Dr. Lowry additionally has ten years experience in the community practice of hematology and oncology. In 2010, Dr. Lowry became chief of hematology/oncology for the Guthrie Health System, a three-hospital tertiary care system serving northern Pennsylvania and southern New York State. He is charged with developing a cutting-edge cancer program that can project into a traditionally rural health care delivery system.
Dr. Lowry has also maintained a career-long interest in regenerative medicine springing from his research and practice experience in stem cell biology. His new role positions him to foster further development of that field. As part of a horizontally and vertically integrated multi-specialty team, he is closely allied with colleagues in cardiology, neurology/neurosurgery, and orthopedics among others with whom he hopes to stimulate the expansion of regenerative techniques.
About Biostem U.S., Corporation
Biostem U.S., Corporation is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered on providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell-related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.
More information on Biostem U.S., Corporation can be obtained through http://www.biostemus.com, or by calling Fox Communications Group 310-974-6821.
Read more here:
Biostem U.S., Corporation Appoints Philip A. Lowry, MD as Chairman of Its Scientific and Medical Board of Advisors
Posted in Cell Therapy
Comments Off on Biostem U.S., Corporation Appoints Philip A. Lowry, MD as Chairman of Its Scientific and Medical Board of Advisors
Bioheart and Ageless Regenerative Partner to Advance Stem Cell Field With New Laboratory Training Program on June 23 …
Posted: May 29, 2012 at 1:23 pm
SUNRISE, Fla., May 29, 2012 (GLOBE NEWSWIRE) -- Bioheart, Inc. (OTCBB:BHRT.OB - News) announced today that it will offer another laboratory training course in partnership with the Ageless Regenerative Institute, an organization dedicated to the standardization of cell regenerative medicine, on Saturday/Sunday June 23-24, 2012. Attendees will participate in hands on, in depth training in laboratory practices in stem cell science at Bioheart, Inc.'s corporate headquarters and clean room in Sunrise, Florida. The course was designed for Laboratory technicians, Students, Physicians and Physician Assistants.
"Attendees will graduate from this one-of-a-kind course with an extensive understanding of stem cell science laboratory practices," said Kristin Comella, Chief Scientific Officer, Bioheart, Inc. "Previous attendees described the course as incredibly well orchestrated providing comprehensive know how for laboratory start up."
An emerging field with tremendous opportunities, adult stem cell research has been shown to regenerate and repair injured or diseased structures via the release of bioactive tissue growth factors and cytokines. This is the second time that The Ageless Regenerative Institute has partnered with Bioheart, Inc. to provide hands-on training in a stem cell laboratory. This course provides instruction regarding how to grow stem cells and perform quality control testing in an actual cGMP facility following FDA regulations.
The course goals and objectives include reviewing stem cell types and characteristics; learning cell culture including plating, trypsinization and harvesting, and cryopreservation; learning quality control tests including cell count, viability, flow cytometry, endotoxin, mycoplasma, sterility; and learning and performing cGMP functions including clean room maintenance, gowning and environmental monitoring.
For information on costs and to register, visit http://www.agelessregen.com or email: info@agelessregen.com.
About Bioheart, Inc.
Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues. Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.
Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com.
About Ageless Regenerative Institute, LLC
The Ageless Regenerative Institute (ARI) is an organization dedicated to the standardization of cell regenerative medicine. The Institute promotes the development of evidence-based standards of excellence in the therapeutic use of adipose-derived stem cells through education, advocacy, and research. ARI has a highly experienced management team with experience in setting up full scale cGMP stem cell manufacturing facilities, stem cell product development & enhancement, developing point-of-care cell production systems, developing culture expanded stem cell production systems, FDA compliance, directing clinical & preclinical studies with multiple cell types for multiple indications, and more. ARI has successfully treated hundreds of patients utilizing these cellular therapies demonstrating both safety and efficacy. For more information about regenerative medicine please visit http://www.agelessregen.com.
Posted in Cell Therapy
Comments Off on Bioheart and Ageless Regenerative Partner to Advance Stem Cell Field With New Laboratory Training Program on June 23 …